On December 18, 2023, Neurogene Inc. closed the transaction. The company has now issued 36,934,089 common shares and 23,964,846 pre-funded warrants for gross proceeds of approximately $95 million. At the closing, the securities were converted into shares of company's common Stock and $0.000001 pre-funded warrants at a rate of 0.0756 shares of common stock per share, and 0.0756 $0.000001 pre-funded warrants for each company's prefunded warrant.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
29.96 USD | +0.30% | -1.74% | +54.59% |
Mar. 22 | North American Morning Briefing : Stocks Struggle After New Records | DJ |
Mar. 21 | William Blair Initiates Neurogene With Outperform Rating | MT |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
762.9 USD | +0.69% | +1.72% | 113B | ||
29.96 USD | +0.30% | -1.74% | 385M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+54.59% | 385M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- NGNE Stock
- News Neurogene Inc.
- Neurogene Inc. announced that it has received $95 million in funding from a group of investors